'Repurposed' anti-parasite drug shows promise as new TB treatment

(Medical Xpress)—A well-established family of drugs used to treat parasitic diseases is showing surprising potential as a therapy for tuberculosis (TB), according to new research from University of British Columbia microbiologists.

The findings, published online this week in the journal , are based on in vitro tests of the avermectin family of drugs. Discovered nearly 40 years ago, the drugs are commonly used in the developing world to eliminate the that cause and elephantiasis but have been thought to be ineffective against . The UBC study shows that in the lab, the drugs actually killed the bacteria that cause TB, including drug resistant forms.

"These drugs are cheap, routinely produced by pharmaceutical companies, and, in many cases, approved for humans use," says UBC researcher Santiago Ramón-García, a co-author on the paper. "So the jump from lab bench to clinic could be much quicker."

"In addition, the drug concentrations effective in vitro indicate members of this family might be very valuable additions to the small repertoire of drugs we have to fight multi-, which have very low probabilities of being cured."

The international collaboration was lead by scientists in UBC's Department of Microbiology and Immunology associated with UBC's Centre for Tuberculosis Research and the Neglected Global Diseases Initiative.

"This underscores the great potential for investments in research to find new uses for approved drugs or synergistic drug combinations," says co-author and UBC microbiologist Charles Thompson.

Further studies are needed to assess the drugs' clinical application for treating TB. UBC researchers are now working with animal models to determine effective dosage levels and regimens. They will also study whether avermectins could be combined with other drugs to create effective therapies.

Related Stories

Drug-resistant tuberculosis rife in China

Dec 11, 2008

Levels of drug-resistant tuberculosis (TB) in China are nearly twice the global average. Nationwide research published in the open access journal BMC Infectious Diseases has shown that almost 10% of Chinese TB cases are re ...

Drug-resistant TB blamed on Indian treatment flaws

Mar 23, 2012

(AP) -- India's inadequate government-run tuberculosis treatment programs and a lack of regulation of the sale of drugs that fight it are responsible for the spiraling number of drug-resistant cases that are difficult to ...

Recommended for you

Ebola in mind, US colleges screen some students

3 hours ago

University students from West Africa may be subject to extra health checks when they arrive to study in the United States as administrators try to insulate their campuses from the worst Ebola outbreak in ...

WHO: More Ebola cases in past week than any other

4 hours ago

The past week has seen the highest increase of Ebola cases since the outbreak in West Africa began, the World Health Organization said Friday, offering more evidence that the crisis is worsening.

Guidelines presented for diagnosing focal liver lesions

19 hours ago

(HealthDay)—Focal liver lesions (FLLs) are mostly benign, and can be diagnosed based on knowledge of their presentation, associated clinical and laboratory features, and natural history, according to clinical ...

User comments